Last reviewed · How we verify

NVX-CoV2705 Vaccine

Novavax · Phase 3 active Biologic

NVX-CoV2705 Vaccine is a Recombinant protein subunit vaccine Biologic drug developed by Novavax. It is currently in Phase 3 development for COVID-19 prevention in adults (variant-specific formulation). Also known as: SARS-CoV-2 rS.

NVX-CoV2705 is a recombinant protein subunit vaccine that presents SARS-CoV-2 spike protein antigens to stimulate adaptive immune responses against COVID-19 variants.

NVX-CoV2705 is a recombinant protein subunit vaccine that presents SARS-CoV-2 spike protein antigens to stimulate adaptive immune responses against COVID-19 variants. Used for COVID-19 prevention in adults (variant-specific formulation).

At a glance

Generic nameNVX-CoV2705 Vaccine
Also known asSARS-CoV-2 rS
SponsorNovavax
Drug classRecombinant protein subunit vaccine
TargetSARS-CoV-2 spike protein
ModalityBiologic
Therapeutic areaImmunology / Infectious Disease
PhasePhase 3

Mechanism of action

The vaccine uses recombinant nanoparticle technology to display stabilized spike proteins from SARS-CoV-2 variants, combined with Matrix-M adjuvant to enhance immunogenicity. This approach triggers both humoral (antibody) and cellular (T-cell) immune responses without using live virus or viral vectors. The vaccine is designed to provide protection against emerging COVID-19 variants, particularly Omicron-derived strains.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about NVX-CoV2705 Vaccine

What is NVX-CoV2705 Vaccine?

NVX-CoV2705 Vaccine is a Recombinant protein subunit vaccine drug developed by Novavax, indicated for COVID-19 prevention in adults (variant-specific formulation).

How does NVX-CoV2705 Vaccine work?

NVX-CoV2705 is a recombinant protein subunit vaccine that presents SARS-CoV-2 spike protein antigens to stimulate adaptive immune responses against COVID-19 variants.

What is NVX-CoV2705 Vaccine used for?

NVX-CoV2705 Vaccine is indicated for COVID-19 prevention in adults (variant-specific formulation).

Who makes NVX-CoV2705 Vaccine?

NVX-CoV2705 Vaccine is developed by Novavax (see full Novavax pipeline at /company/novavax).

Is NVX-CoV2705 Vaccine also known as anything else?

NVX-CoV2705 Vaccine is also known as SARS-CoV-2 rS.

What drug class is NVX-CoV2705 Vaccine in?

NVX-CoV2705 Vaccine belongs to the Recombinant protein subunit vaccine class. See all Recombinant protein subunit vaccine drugs at /class/recombinant-protein-subunit-vaccine.

What development phase is NVX-CoV2705 Vaccine in?

NVX-CoV2705 Vaccine is in Phase 3.

What are the side effects of NVX-CoV2705 Vaccine?

Common side effects of NVX-CoV2705 Vaccine include Injection site pain, Fatigue, Myalgia, Headache, Fever.

What does NVX-CoV2705 Vaccine target?

NVX-CoV2705 Vaccine targets SARS-CoV-2 spike protein and is a Recombinant protein subunit vaccine.

Related